Remedy Robotics
Vascular intervention without borders
Every year, lack of access to stroke care leads to millions of lives lost and millions of cases of permanent disability. Though cardiovascular disease remains the world’s leading cause of death, with stroke alone exacting a staggering $891 billion economic toll annually, fewer than three percent of eligible stroke patients receive the care they need. The bottleneck? A critical shortage of specialized physicians and equipment.
Remedy Robotics is changing that. By combining AI with advanced robotics to manipulate tiny catheters with precision, Remedy’s N1 System, currently in development, is designed to perform gold-standard endovascular procedures onsite, remotely, or even autonomously. Backing companies that bring deep tech innovation to bear on the biggest challenges the world faces is what we do here at DCVC, which is why we’re thrilled to lead the $62 million Series B Remedy announced earlier today.
Over the past year, the company has hit a number of milestones on the road to bringing this life-saving technology into real-world clinical use. In October 2025, in collaboration with world-renowned surgeon Dr. Vitor Mendes Pereira at St. Michael’s Hospital in Toronto, Remedy’s N1 System successfully demonstrated the first-ever entirely remote neurointerventional procedures in human patients. The company is also moving quickly on the regulatory front and will be using this new funding to support a pivotal clinical trial in partnership with leading clinicians at the University of California. Remedy now works with more than 100 hospital partners worldwide and will soon deploy additional prototype systems through partnerships with SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Under the leadership of CEO Dr. David Bell and CTO Dr. Jake Sganga, Remedy is realizing a bold vision: ensuring your geography no longer dictates your chance of surviving a stroke. By pioneering medical robotics, the Remedy team is democratizing life-saving care for patients everywhere.